Vigilare Wealth Management Aurinia Pharmaceuticals Inc. Transaction History

Vigilare Wealth Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 20, 2022	SELL	$6.66 - $12.39 $19,980 - $37,170	-3,000 Reduced 19.63%	12,285 $92,000
Q2 2022 Jul 11, 2022	SELL	$8.95 - $12.8 $118,945 - $170,112	-13,290 Reduced 46.51%	15,285 $154,000
Q1 2022 Apr 06, 2022	SELL	$10.05 - $22.48 $63,817 - $142,748	-6,350 Reduced 18.18%	28,575 $354,000
Q4 2021 Jan 07, 2022	BUY	$17.78 - $33.08 $132,549 - $246,611	7,455 Added 27.14%	34,925 $799,000
Q3 2021 Oct 19, 2021	BUY	$10.93 - $23.55 $300,247 - $646,918	27,470 New	27,470 $608,000
Q1 2021 Apr 29, 2021	SELL	$12.3 - $18.73 $224,475 - $341,822	-18,250 Closed	0 $0
Q4 2020 Jan 14, 2021	BUY	$12.94 - $16.05 $71,558 - $88,756	5,530 Added 43.47%	18,250 $252,000
Q3 2020 Oct 15, 2020	BUY	$13.19 - $16.66 $1,582 - $1,999	120 Added 0.95%	12,720 $187,000
Q2 2020 Jul 20, 2020	BUY	$14.12 - $18.33 $1,412 - $1,832	100 Added 0.8%	12,600 $205,000
Q1 2020 May 04, 2020	BUY	$11.34 - $21.46 $141,750 - $268,250	12,500 New	12,500 $181,000

209

58.2M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Vigilare Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Vigilare Wealth Management with notifications on news.